{"title":"皂苷能改善脑缺血损伤并调节星形胶质细胞的谷氨酸代谢途径","authors":"Xiaoyu Zheng, Hongwei Zhang, Yehao Zhang, Zhao Ding, Zishan Huang, Haoran Li, Mingjiang Yao, Wenting Song, Jianxun Liu","doi":"10.3389/fphar.2024.1472100","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aim: </strong>Salidroside (SA) is the main active component of <i>Rhodiola rosea</i> L., with potential in treating cardiovascular and cerebrovascular diseases and cerebral ischemia. However, its efficacy and mechanism in cerebral ischemia remain unclear, particularly regarding its effect on glutamate (Glu) metabolism. In this paper, we aimed to investigate the efficacy of SA in treating cerebral ischemia and its pharmacological mechanism.</p><p><strong>Experimental procedure: </strong>We studied the effects of SA on SD rats with cerebral ischemia, evaluating neurobehavior, cerebral water content, infarct size, and brain microstructure. We also assessed its impact on glial fibrillary acidic protein (GFAP), glutamine synthetase (GS), and glutamate transporter 1 (GLT-1) proteins using immunohistochemistry and Western blot. Additionally, we used SVGp12 cells to simulate cerebral ischemia and measured Glu levels and used Western blot to observe the level of GS and GLT-1.</p><p><strong>Results: </strong>SA improved neural function, reduced infarct size, and regulated GSH and Glu levels in rats. In cell experiments, SA increased cell viability and decreased Glu concentration after ischemia induction. It also regulated the expression of GFAP, GS, and GLT-1.</p><p><strong>Conclusion: </strong>SA alleviates cerebral ischemia-induced injury by acting on astrocytes, possibly through regulating the glutamate metabolic pathway.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"15 ","pages":"1472100"},"PeriodicalIF":4.4000,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11588439/pdf/","citationCount":"0","resultStr":"{\"title\":\"Salidroside ameliorates cerebral ischemic injury and regulates the glutamate metabolism pathway in astrocytes.\",\"authors\":\"Xiaoyu Zheng, Hongwei Zhang, Yehao Zhang, Zhao Ding, Zishan Huang, Haoran Li, Mingjiang Yao, Wenting Song, Jianxun Liu\",\"doi\":\"10.3389/fphar.2024.1472100\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and aim: </strong>Salidroside (SA) is the main active component of <i>Rhodiola rosea</i> L., with potential in treating cardiovascular and cerebrovascular diseases and cerebral ischemia. However, its efficacy and mechanism in cerebral ischemia remain unclear, particularly regarding its effect on glutamate (Glu) metabolism. In this paper, we aimed to investigate the efficacy of SA in treating cerebral ischemia and its pharmacological mechanism.</p><p><strong>Experimental procedure: </strong>We studied the effects of SA on SD rats with cerebral ischemia, evaluating neurobehavior, cerebral water content, infarct size, and brain microstructure. We also assessed its impact on glial fibrillary acidic protein (GFAP), glutamine synthetase (GS), and glutamate transporter 1 (GLT-1) proteins using immunohistochemistry and Western blot. Additionally, we used SVGp12 cells to simulate cerebral ischemia and measured Glu levels and used Western blot to observe the level of GS and GLT-1.</p><p><strong>Results: </strong>SA improved neural function, reduced infarct size, and regulated GSH and Glu levels in rats. In cell experiments, SA increased cell viability and decreased Glu concentration after ischemia induction. It also regulated the expression of GFAP, GS, and GLT-1.</p><p><strong>Conclusion: </strong>SA alleviates cerebral ischemia-induced injury by acting on astrocytes, possibly through regulating the glutamate metabolic pathway.</p>\",\"PeriodicalId\":12491,\"journal\":{\"name\":\"Frontiers in Pharmacology\",\"volume\":\"15 \",\"pages\":\"1472100\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2024-11-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11588439/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/fphar.2024.1472100\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fphar.2024.1472100","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
摘要
背景和目的：水杨梅苷（SA）是红景天的主要活性成分，具有治疗心脑血管疾病和脑缺血的潜力。然而，其对脑缺血的疗效和机制仍不清楚，尤其是对谷氨酸（Glu）代谢的影响。本文旨在研究 SA 治疗脑缺血的疗效及其药理机制：实验过程：我们研究了 SA 对 SD 脑缺血大鼠的影响，评估了神经行为、脑含水量、梗塞大小和脑微结构。我们还使用免疫组化和 Western 印迹法评估了 SA 对神经胶质纤维酸性蛋白（GFAP）、谷氨酰胺合成酶（GS）和谷氨酸转运体 1（GLT-1）蛋白的影响。此外，我们还使用 SVGp12 细胞模拟脑缺血，测量 Glu 水平，并使用 Western 印迹观察 GS 和 GLT-1 的水平：结果：SA能改善大鼠的神经功能，缩小梗死面积，调节GSH和Glu水平。在细胞实验中，SA 提高了细胞活力，降低了缺血诱导后的 Glu 浓度。它还能调节 GFAP、GS 和 GLT-1 的表达：结论：SA 可能通过调节谷氨酸代谢途径，作用于星形胶质细胞，从而减轻脑缺血诱导的损伤。
Salidroside ameliorates cerebral ischemic injury and regulates the glutamate metabolism pathway in astrocytes.
Background and aim: Salidroside (SA) is the main active component of Rhodiola rosea L., with potential in treating cardiovascular and cerebrovascular diseases and cerebral ischemia. However, its efficacy and mechanism in cerebral ischemia remain unclear, particularly regarding its effect on glutamate (Glu) metabolism. In this paper, we aimed to investigate the efficacy of SA in treating cerebral ischemia and its pharmacological mechanism.
Experimental procedure: We studied the effects of SA on SD rats with cerebral ischemia, evaluating neurobehavior, cerebral water content, infarct size, and brain microstructure. We also assessed its impact on glial fibrillary acidic protein (GFAP), glutamine synthetase (GS), and glutamate transporter 1 (GLT-1) proteins using immunohistochemistry and Western blot. Additionally, we used SVGp12 cells to simulate cerebral ischemia and measured Glu levels and used Western blot to observe the level of GS and GLT-1.
Results: SA improved neural function, reduced infarct size, and regulated GSH and Glu levels in rats. In cell experiments, SA increased cell viability and decreased Glu concentration after ischemia induction. It also regulated the expression of GFAP, GS, and GLT-1.
Conclusion: SA alleviates cerebral ischemia-induced injury by acting on astrocytes, possibly through regulating the glutamate metabolic pathway.
期刊介绍：
Frontiers in Pharmacology is a leading journal in its field, publishing rigorously peer-reviewed research across disciplines, including basic and clinical pharmacology, medicinal chemistry, pharmacy and toxicology. Field Chief Editor Heike Wulff at UC Davis is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
